CRISPR Therapeutics (CRSP, Financial) received a reaffirmation of its positive outlook as Chardan Capital analyst Geulah Livshits maintained the stock's "Buy" rating. The analyst's price target remains steady at $82.00, as announced on June 26, 2025.
This latest assessment by Chardan Capital underscores continued confidence in the performance and potential of CRSP. With the price target holding firm at $82.00, investors may find reassurance in the stock's future prospects. As of this analyst update, there has been no change in the target price since the last evaluation, reflecting a stable outlook from the analyst.
Chardan Capital's commitment to the "Buy" rating suggests a positive sentiment towards CRISPR Therapeutics (CRSP, Financial), presenting a bullish perspective on the company's trajectory in the biotechnology sector. Investors should note that these ratings are indicative of the analyst's expectations for the stock performance based on current market scenarios.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for CRISPR Therapeutics AG (CRSP, Financial) is $80.80 with a high estimate of $268.00 and a low estimate of $32.00. The average target implies an upside of 73.77% from the current price of $46.50. More detailed estimate data can be found on the CRISPR Therapeutics AG (CRSP) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, CRISPR Therapeutics AG's (CRSP, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CRISPR Therapeutics AG (CRSP, Financial) in one year is $34.13, suggesting a downside of 26.59% from the current price of $46.495. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CRISPR Therapeutics AG (CRSP) Summary page.
